Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Glycoprotein IIb/IIIa receptors and primary stenting in acute myocardial infarction
Autore:
Montalescot, G; Choussat, R; Collet, JP;
Indirizzi:
Ctr Hop Univ, Paris, France Ctr Hop Univ Paris FranceCtr Hop Univ, Paris, France
Titolo Testata:
EUROPEAN HEART JOURNAL SUPPLEMENTS
fascicolo: A, volume: 3, anno: 2001,
pagine: A3 - A7
SICI:
1520-765X(200105)3:A<A3:GIRAPS>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
TRANSLUMINAL CORONARY ANGIOPLASTY; CONVENTIONAL BALLOON ANGIOPLASTY; THROMBOLYTIC THERAPY; BLOCKADE; PLACEMENT; TRIAL; ABCIXIMAB; OUTCOMES;
Keywords:
GP IIb/IIIa receptor inhibitor; primary stenting; acute myocardial infarction; percutaneous transluminal coronary angioplasty; fibrinolysis;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
30
Recensione:
Indirizzi per estratti:
Indirizzo: Montalescot, G Univ Pitie Salpetriere, Dept Cardiol, 47 Blvd de Hop, F-75651 Paris, France Univ Pitie Salpetriere 47 Blvd de Hop Paris France F-75651
Citazione:
G. Montalescot et al., "Glycoprotein IIb/IIIa receptors and primary stenting in acute myocardial infarction", EUR H J SUP, 3(A), 2001, pp. A3-A7

Abstract

The past 15 years have seen great progress in the treatment of acute myocardial infarction (MI), with the development of thrombolytic agents and catheter-based reperfusion strategies such as percutaneous transluminal coronary angioplasty (PTCA). Because both thrombolytics and PTCA have limitations in achieving large-vessel patency, stenting has been adopted as the treatment modality of choice for planned elective revascularization. In addition, an increasing number of studies have indicated that the class of antiplatelet drugs known as glycoprotein (GP) IIb/IIIa receptor inhibitors can reduceischaemic events following both elective and acute percutaneous coronary interventions. The results have been unequivocally positive regarding the benefits of these agents in PTCA procedures, but less information is available on their use with primary stenting in acute MI. This article reviews the rationale and emerging evidence supporting the use of GP IIb/IIIa receptor inhibitors in conjunction with primary stenting for acute MI.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 19:37:22